TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:44
Qilian International Holding Group Ltd ( QLI ) https://www.qlsyy.net
0.43USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
China
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-43.95%
QLI
SPY
30.72%
QLI
0.00%
SPY
112.82%
QLI
0.00%
SPY
201.04%
QLI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
15.44
1.12
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
17.35
0.32
0.28
0.00
11.57
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
18.77
17.08
0.00
Other Earnings and Cash Flow Stats:
Qilian International Holding Group Ltd ( QLI ) Net Income TTM ($MM) is 0.00
Qilian International Holding Group Ltd ( QLI ) Operating Income TTM ($MM) is 0.00
Qilian International Holding Group Ltd ( QLI ) Owners' Earnings Annual ($MM) is 9.29
Qilian International Holding Group Ltd ( QLI ) Current Price to Owners' Earnings ratio is 1.66
Qilian International Holding Group Ltd ( QLI ) EBITDA TTM ($MM) is 0.00
Qilian International Holding Group Ltd ( QLI ) EBITDA Margin is 0.00%
Capital Allocation:
Qilian International Holding Group Ltd ( QLI ) has paid 0.05 dividends per share and bought back 0.0 million shares in the past 12 months
Qilian International Holding Group Ltd ( QLI ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Qilian International Holding Group Ltd ( QLI ) Interest-bearing Debt ($MM) as of last quarter is 0
Qilian International Holding Group Ltd ( QLI ) Annual Working Capital Investments ($MM) are -17
Qilian International Holding Group Ltd ( QLI ) Book Value ($MM) as of last quarter is 54
Qilian International Holding Group Ltd ( QLI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Qilian International Holding Group Ltd ( QLI ) has 14 million in cash on hand as of last quarter
Qilian International Holding Group Ltd ( QLI ) has 9 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Qilian International Holding Group Ltd ( QLI ) has 35 common shares outstanding as of last quarter
Qilian International Holding Group Ltd ( QLI ) has 0 million USD of preferred stock value
Academic Scores:
Qilian International Holding Group Ltd ( QLI ) Altman Z-Score is 1.69 as of last quarter
Qilian International Holding Group Ltd ( QLI ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Qilian International Holding Group Ltd ( QLI ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Qilian International Holding Group Ltd ( QLI ) for the amount of $ on
77.45% of Qilian International Holding Group Ltd ( QLI ) is held by insiders, and 0.07% is held by institutions
Qilian International Holding Group Ltd ( QLI ) went public on 2021-01-12
Other Qilian International Holding Group Ltd ( QLI ) financial metrics:
FCF:0.00
Unlevered Free Cash Flow:17.62
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:200.81
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:0.00
Buffet's Owners Earnings:9.29
Price to Owner's Earnings:1.66
About Qilian International Holding Group Ltd ( QLI ) :
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.